Stories
Solara Active Pharma Shares Surge 18% After Strong Q2 Turnaround
C
CNBC TV18•16-10-2026, 14:55
Solara Active Pharma Shares Surge 18% After Strong Q2 Turnaround
- •Solara Active Pharma Sciences reported a consolidated net profit of ₹28.5 crore in Q2 FY27, swinging from a loss of ₹10 crore in the year-ago period.
- •Revenue rose 33.1% year on year to ₹417.3 crore, and EBITDA more than doubled to ₹76.82 crore.
- •The company recorded its highest quarterly EBITDA and profit after tax in five years, with EBITDA margin expanding to 18.41%.
- •The base business grew revenue by 37% to ₹327.3 crore, while the ibuprofen segment narrowed its EBITDA loss sharply to ₹20 lakh.
- •Net debt to EBITDA declined to around 1.8 times from 3.2 times at the end of FY26, strengthening the company balance sheet.
Key Questions Answered
Solara Active Pharma Sciences reported a consolidated net profit of ₹28.5 crore for Q2 FY27, turning around from a loss of ₹10 crore in the same period last year. Revenue grew 33.1% year on year to ₹417.3 crore, and EBITDA more than doubled to ₹76.82 crore.
The base business grew 37% year on year to ₹327.3 crore, while the ibuprofen segment saw revenue rise 21% to ₹90.5 crore with its EBITDA loss narrowing sharply to ₹20 lakh.
Solara's net debt to EBITDA ratio declined to approximately 1.8 times down from 3.2 times at the end of FY26, providing the company with more room to invest in growth.
